Patents by Inventor Wayne R. Danter
Wayne R. Danter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9284275Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: GrantFiled: November 8, 2013Date of Patent: March 15, 2016Assignee: CRITICAL OUTCOME TECHNOLOGIES INC.Inventor: Wayne R. Danter
-
Publication number: 20150019190Abstract: The disclosure relates to a programmable cancer cell model that may be customized to simulate the effect of gene mutations, for example mutations identified from a particular cancer patient's tissue sample. The simulation may be used to assess the likelihood of a candidate treatment resulting in stable remission for the patient. The model makes use of a fuzzy cognitive map (FCM) simulator that employs a matrix to represent healthy cell signaling relationships and an input disease vector representing one or more genetic mutations. The disease state vector is multiplied by the matrix to produce a stable diseased cell state vector after multiple iterations. A candidate treatment may then be proposed, based upon the diseased cell state vector. After multiple iterations with a treatment vector, the efficacy of the proposed treatment on the patient's particular cancer can be assessed, reducing reliance on the traditional trial and error approach.Type: ApplicationFiled: December 14, 2012Publication date: January 15, 2015Inventor: Wayne R. Danter
-
Patent number: 8895556Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.Type: GrantFiled: March 13, 2013Date of Patent: November 25, 2014Assignee: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Cheuk Kun Lau
-
Patent number: 8822475Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: February 19, 2013Date of Patent: September 2, 2014Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Publication number: 20140072555Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: ApplicationFiled: November 8, 2013Publication date: March 13, 2014Applicant: Critical Outcome Technologies Inc.Inventor: Wayne R. Danter
-
Patent number: 8580792Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: GrantFiled: February 1, 2012Date of Patent: November 12, 2013Assignee: Critical Outcome Technologies Inc.Inventor: Wayne R. Danter
-
Publication number: 20130231345Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.Type: ApplicationFiled: March 13, 2013Publication date: September 5, 2013Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.Inventors: Wayne R. Danter, Cheuk Kun Lau
-
Patent number: 8466151Abstract: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.Type: GrantFiled: December 24, 2008Date of Patent: June 18, 2013Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R Danter, Cheuk Kun Kun Lau
-
Patent number: 8420643Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: December 2, 2011Date of Patent: April 16, 2013Assignee: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8367675Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: July 25, 2011Date of Patent: February 5, 2013Assignee: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8252800Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: GrantFiled: July 28, 2009Date of Patent: August 28, 2012Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth
-
Publication number: 20120195887Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: ApplicationFiled: February 1, 2012Publication date: August 2, 2012Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventor: Wayne R. Danter
-
Publication number: 20120077820Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: ApplicationFiled: December 2, 2011Publication date: March 29, 2012Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8138191Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: GrantFiled: July 17, 2009Date of Patent: March 20, 2012Assignee: Critical Outcome Technologies Inc.Inventor: Wayne R. Danter
-
Publication number: 20110281887Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: ApplicationFiled: July 25, 2011Publication date: November 17, 2011Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Patent number: 8034815Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.Type: GrantFiled: January 11, 2008Date of Patent: October 11, 2011Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
-
Publication number: 20110152281Abstract: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.Type: ApplicationFiled: December 24, 2008Publication date: June 23, 2011Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.Inventors: Wayne R. Danter, Cheuk Kun Lau
-
Publication number: 20100015140Abstract: A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.Type: ApplicationFiled: July 17, 2009Publication date: January 21, 2010Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.Inventor: Wayne R. Danter
-
Patent number: 7629347Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.Type: GrantFiled: October 9, 2003Date of Patent: December 8, 2009Assignee: Critical Outcome Technologies, Inc.Inventors: Wayne R. Danter, George Ma, Natalie Lazarowych, Stephen Houldsworth, Martyn Brown, Ghenadie Rusu, Jianhua Zhong
-
Publication number: 20090298855Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:Type: ApplicationFiled: July 28, 2009Publication date: December 3, 2009Applicant: Critical Outcome Technologies Inc.Inventors: Wayne R. Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth